PMID- 35778526
OWN - NLM
STAT- MEDLINE
DCOM- 20220707
LR  - 20220909
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jul 1
TI  - Identification of pyroptosis-related long non-coding RNAs with prognosis and 
      therapy in lung squamous cell carcinoma.
PG  - 11206
LID - 10.1038/s41598-022-15373-6 [doi]
LID - 11206
AB  - Pyroptosis is a type of programmed cell death with an intense inflammatory 
      response. Previous studies have shown that pyroptosis plays an important role in 
      the pathogenesis and progression of lung cancer. However, the prognostic value 
      and drug targets of pyroptosis-related lncRNAs in lung squamous cell carcinoma 
      (LSCC) have never been studied. In the present study, we identified 1468 
      pyroptosis-related lncRNAs in LSCC by performing Pearson correlation analysis 
      between the pyroptosis-related genes and the lncRNAs from The Cancer Genome Atlas 
      (TCGA) and Gene Expression Omnibus (GEO) database. The whole set was divided into 
      a training and a test set with a 1:1 ratio. Univariate Cox regression and least 
      absolute shrinkage and selection operator (LASSO) analyses were conducted to 
      establish an 11 multilncRNA signature in the three sets. The signature divided 
      LSCC patients into the low-risk and the high-risk groups. Kaplan-Meier analysis 
      and receiver operating characteristic (ROC) indicated that the prognostic 
      signature had a promising predictive capability for LSCC patients. Besides, the 
      association of microenvironment and immunotherapy response with signature was 
      also analyzed. Moreover, 28 potential compounds targeting signature were screened 
      as possible drugs to treat LSCC. Finally, a nomogram model was constructed to 
      offer the quantitative prediction and net benefit for the prognosis of LSCC 
      patients. In conclusion, the 11 pyroptosis-related lncRNAs and their signature 
      may be promising prognostic factors and therapeutic targets for patients with 
      LSCC.
CI  - (c) 2022. The Author(s).
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, 
      Fujian, People's Republic of China.
FAU - Wang, Yuzhi
AU  - Wang Y
AD  - Department of Laboratory Medicine, People's Hospital of Deyang City, Deyang, 
      618000, Sichuan, People's Republic of China.
FAU - Yin, Xiaoqing
AU  - Yin X
AD  - Fujian University of Traditional Chinese Medicine, Fuzhou, 350001, Fujian, 
      People's Republic of China.
FAU - Huang, Yi
AU  - Huang Y
AD  - Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, 
      Fujian, People's Republic of China. hyi8070@126.com.
AD  - Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, 
      Fujian, People's Republic of China. hyi8070@126.com.
AD  - Center for Experimental Research in Clinical Medicine, Fujian Provincial 
      Hospital, Fuzhou, 350001, Fujian, People's Republic of China. hyi8070@126.com.
AD  - Central Laboratory, Fujian Provincial Hospital, Fuzhou, 350001, Fujian, People's 
      Republic of China. hyi8070@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220701
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - *Carcinoma, Non-Small-Cell Lung/genetics
MH  - *Carcinoma, Squamous Cell/drug therapy/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung/pathology
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Prognosis
MH  - Pyroptosis/genetics
MH  - *RNA, Long Noncoding/genetics/metabolism
MH  - Tumor Microenvironment/genetics
PMC - PMC9249737
COIS- The authors declare no competing interests.
EDAT- 2022/07/02 06:00
MHDA- 2022/07/08 06:00
PMCR- 2022/07/01
CRDT- 2022/07/01 23:26
PHST- 2022/01/11 00:00 [received]
PHST- 2022/06/23 00:00 [accepted]
PHST- 2022/07/01 23:26 [entrez]
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/07/08 06:00 [medline]
PHST- 2022/07/01 00:00 [pmc-release]
AID - 10.1038/s41598-022-15373-6 [pii]
AID - 15373 [pii]
AID - 10.1038/s41598-022-15373-6 [doi]
PST - epublish
SO  - Sci Rep. 2022 Jul 1;12(1):11206. doi: 10.1038/s41598-022-15373-6.